Synopsis: Syngene International posted a sharp 886 percent climb QoQ in consolidated net profit for Q4FY26 to Rs.317 crore, even as revenue grew a modest 3 percent YoY to Rs.3,739 crore; the board has recommended a dividend of Rs.1.25 per share.
A Bengaluru-based contract research and manufacturing company came into focus on April 29, 2026, after reporting its audited results for the quarter and year ended March 31, 2026. The headline numbers were shaped less by operational performance than by a series of non-recurring charges that together stripped out over Rs.760 crore before tax from the full-year consolidated results.
With a market capitalization of Rs. 19,089 crore, the shares of Syngene International Ltd were trading at Rs. 471.1 per share, Whent up to 20 percent upper circuit from its previous closing price of Rs. 432.15 apiece. It is trading at a P/E of 54.98.
Consolidated revenue from operations for FY26 came in at Rs.3,739 crore, up 2.6 percent from Rs.3,642 crore in FY25. That is a meaningful slowdown for a company that was compounding revenue at 12 percent annually over the prior three years. Q4 FY26 revenue stood at Rs.1,036.5 crore, modestly ahead of the Rs.1,018 crore in the year-ago quarter, suggesting the business returned to growth after a weak first half.
Operating profit before exceptional items held up at Rs.4,875 million (consolidated), but after exceptional charges of Rs.766 million, profit before tax collapsed to Rs.4,109 million versus Rs.6,599 million in FY25. The net result: consolidated PAT of Rs.317 crore against Rs.496 crore the previous year, a 36 percent decline.
The exceptional items warrant scrutiny. The larger component originated from the government’s notification of four Labour Codes in November 2025. A revised wage definition pushed up gratuity obligations across the group, and the company booked Rs.462 million as exceptional expense at the consolidated level for FY26 (net of a partial reversal of Rs.244 million in Q4 after remeasurement under revised remuneration structures).
The second charge (Rs.304 million in termination benefits extended to employees during Q4) implies a degree of workforce restructuring. Both items are disclosed as non-recurring, but the labour code impact carries tail risk since the government has yet to finalise all central and state rules, meaning further accounting adjustments cannot be ruled out.
On the cost side, employee benefits expenses rose from Rs.983.9 crore in FY25 to Rs.1,104.9 crore in FY26, a jump of over 12 percent, against revenue growth of less than 3 percent. The mismatch is worth monitoring; it suggests Syngene absorbed significant headcount costs ahead of the revenue ramp it presumably expects from its biologics manufacturing buildout.
The board recommended a final dividend of Rs.1.25 per equity share of Rs.10 for FY26, with a record date of June 26, 2026. Payment is conditional on shareholder approval at the 33rd AGM, scheduled for July 29, 2026.
Business Overview
Established in 1993 as a Biocon subsidiary, Syngene International is India’s first integrated Contract Research, Development and Manufacturing (CRDMO) services company. The company serves over 400 active clients, including 13 of the top 15 global pharma companies, and employs over 6,000 scientists across 1.9 million square feet of infrastructure.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Syngene Stock Hits 20% UC After Reporting 886% Jump in Q4 Profits QoQ appeared first on Trade Brains.